MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

Search

BioMarin Pharmaceutical Inc

Abierto

SectorSanidad

62.85 0.29

Resumen

Variación precio

24h

Actual

Mínimo

61.49

Máximo

62.77

Métricas clave

By Trading Economics

Ingresos

19M

125M

Ventas

1.6M

747M

P/B

Media del Sector

26.539

57.333

BPA

0.92

Margen de beneficios

16.719

Empleados

3,040

EBITDA

39M

195M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+57.54% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-729M

11B

Apertura anterior

62.56

Cierre anterior

62.85

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

BioMarin Pharmaceutical Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 jun 2024, 17:41 UTC

Principales Movimientos del Mercado

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21 ago 2024, 11:30 UTC

Principales Noticias

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Comparación entre iguales

Cambio de precio

BioMarin Pharmaceutical Inc previsión

Precio Objetivo

By TipRanks

57.54% repunte

Estimación a 12 Meses

Media 97.58 USD  57.54%

Máximo 126 USD

Mínimo 70 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioMarin Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

16

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

61.5 / 63.39Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.